What is the CVR number of Hemab ApS?

Hemab ApS is registered with CVR / Virk under CVR 40837590.

How many employees does Hemab ApS have?

Hemab ApS employs 42 people as of the latest annual report.

Benny Sørensen is the CEO of Hemab ApS, in role since 2022.

John Michael Maraganore chairs the board of Hemab ApS, in role since 2022.

Hemab ApS's registered address is Nordre Fasanvej 215.

APSActive

CVR 40837590Nordre Fasanvej 215, 2000 FrederiksbergManufacture of pharmaceutical preparations· NACE 2120Est. 2019 · 6 years old42 employees

Actively employed in the business

Name	Role	Member since
Current (2)
BS Benny Sørensen Chief Executive Officer	Chief Executive Officer	2022
MN Mads Nikolaj Behrndt-Eriksen Management	Management	2021

Former (1)


JH Johan Henrik Faber Management	Management	2019 – 2023

Non-executive oversight

Name	Role	Member since
Current (4)
BS Benny Sørensen Board of Directors	Board of Directors	2023
LC Linda Catharina Bain Board of Directors	Board of Directors	2022
JM John Michael Maraganore Chairman	Chairman	2022
AK Akshay Krishnadas Vaishnaw Board of Directors	Board of Directors	2024

Former (12)


JS Jørgen Søberg Petersen Chairman	Chairman	2020 – 2022
JA Joseph Anderson Board of Directors	Board of Directors	2025 – 2026
MS Mårten Steen Board of Directors	Board of Directors	2021 – 2025
DB Daniel Becker Board of Directors	Board of Directors	2023 – 2026
SE Søren Erik Bjørn Board of Directors	Board of Directors	2020 – 2020
CP Camilla Petrycer Hansen Board of Directors	Board of Directors	2020 – 2021
JH Johan Henrik Faber Board of Directors	Board of Directors	2019 – 2021
TD Thomas Dal Stenfeldt Batchelor Board of Directors	Board of Directors	2021 – 2023
LA Laura Anne Tadvalkar Board of Directors	Board of Directors	2021 – 2026
KS Kim Stengaard Holmsted Chairman	Chairman	2019 – 2020
HH Hans Heugh Wandall Chairman	Chairman	2020 – 2020
UC Uya Chuluunbaatar Board of Directors	Board of Directors	2023 – 2026

As of last annual report

Shareholder	Type	Ownership	Votes	Since
Hemab Therapeutics Holdings, Inc.	Company	100%	100%	2026
Ebumab Holding ApS	Company	5–9.99%	5–9.99%	2023
RA Capital Nexus Fund II, L.P.	Individual	5–9.99%	5–9.99%	2023
HealthCap VIII L.P.	Individual	5–9.99%	5–9.99%	2025
Novo Holdings A/S	Company	15–19.99%	15–19.99%	2025
SMALLCAP World Fund, Inc.	Company	5–9.99%	5–9.99%	2025
AVORO VENTURES FUND L.P.	Individual	5–9.99%	5–9.99%	2023
AI DEN-MAB LLC	Company	10–14.99%	10–14.99%	2025
GV1 Holding ApS	Company	5–9.99%	5–9.99%	2020
Sofinnova Crossover II S.L.P.	Individual	5–9.99%	5–9.99%	2025
RA Capital Healthcare Fund, L.P.	Individual	10–14.99%	10–14.99%	2025
DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD.	Company	5–9.99%	5–9.99%	2025

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.